

# Sonam Puri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1470165/publications.pdf>

Version: 2024-02-01

12  
papers

374  
citations

1477746

6  
h-index

1199166

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2022, 24, 113-123.	1.8	4
2	Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. <i>Cancers</i> , 2022, 14, 690.	1.7	2
3	Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 576-585.	0.8	20
4	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	0.5	9
5	Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?. <i>JCO Precision Oncology</i> , 2021, 5, 408-414.	1.5	7
6	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.	0.7	9
7	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
8	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. <i>Oncotarget</i> , 2021, 12, 2449-2458.	0.8	5
9	Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1783.	1.3	2
10	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. <i>Cancer Cell</i> , 2020, 38, 60-78.e12.	7.7	262
11	Locally Advanced, Unresectable Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 31.	1.8	17
12	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	34